Pharsight

Brilinta patents expiration

BRILINTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6251910 ASTRAZENECA 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Jul, 2018

(5 years ago)

US6525060 ASTRAZENECA Triazolo(4,5-d)pyrimidine compounds
Dec, 2019

(4 years ago)

US7250419 ASTRAZENECA Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Dec, 2019

(4 years ago)

US7265124 ASTRAZENECA Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
Jul, 2021

(2 years ago)

USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6251910 ASTRAZENECA 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Jul, 2018

(5 years ago)

US6525060 ASTRAZENECA Triazolo(4,5-d)pyrimidine compounds
Dec, 2019

(4 years ago)

US7250419 ASTRAZENECA Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Dec, 2019

(4 years ago)

US7265124 ASTRAZENECA Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
Jul, 2021

(2 years ago)

USRE46276

(Pediatric)

ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Apr, 2025

(11 months from now)

US8425934 ASTRAZENECA Pharmaceutical compositions
Apr, 2030

(5 years from now)

US8425934

(Pediatric)

ASTRAZENECA Pharmaceutical compositions
Oct, 2030

(6 years from now)

US10300065 ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jan, 2036

(11 years from now)

US10300065

(Pediatric)

ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jul, 2036

(12 years from now)

Brilinta is owned by Astrazeneca.

Brilinta contains Ticagrelor.

Brilinta has a total of 14 drug patents out of which 8 drug patents have expired.

Expired drug patents of Brilinta are:

  • US6251910
  • US6525060
  • US7250419
  • US7265124
  • US6251910
  • US6525060
  • US7250419
  • US7265124

Brilinta was authorised for market use on 03 September, 2015.

Brilinta is available in tablet;oral dosage forms.

Brilinta can be used as reduction of the rate of thrombotic events in patients with acute coronary syndrome, reduction of the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack, treatment of thrombotic stroke, reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction, reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily, reduction of the rate of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events.

Drug patent challenges can be filed against Brilinta from 09 November, 2024.

The generics of Brilinta are possible to be released after 27 July, 2036.

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-848) Nov 05, 2023
M(M-283) May 09, 2025
Pediatric Exclusivity(PED) Nov 09, 2025
New Indication(I-851) May 28, 2023
New Strength(NS) Sep 03, 2018
New Indication(I-714) Sep 03, 2018
New Chemical Entity Exclusivity(NCE) Jul 20, 2016

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TICAGRELOR ingredient

NCE-1 date: 09 November, 2024

Market Authorisation Date: 03 September, 2015

Treatment: Reduction of the rate of thrombotic events in patients with acute coronary syndrome; Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspir...

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents